|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy(STRATEGY):a multicenter,randomized,controlled,non-inferiority clinical trial显示文摘Despite the current guideline's recommendation of a timely stepwise intensification therapy,the 'clinical inertia',termed as the delayed treatment intensification,commonly exists in the real world,which may be partly due to the relatively little substantial evidence and no clear consensus regarding the efficacy and safety of triple oral agents in patients inadequately controlled with dual therapy.In this clinical trial performed in 237 centers in China,5,535 type 2 diabetic patients inadequately controlled by previous therapies were treated with a stable metformin/sitagliptin dual therapy for 20 weeks.The patients who did not reach the glycated hemoglobin A1c(HbA1c) goal were then further randomized into glimepiride,gliclazide,repaglinide,or acarbose group for an additional 24-week triple therapy.A mean HbAlc reduction of 0.85%was observed when sitagliptin was added to the patients inadequately controlled with metformin in 16 weeks.Further HbAlc reductions in the 24-week triple therapy stage were 0.65%in glimepiride group,0.70%in gliclazide group,0.61%in repaglinide group,and 0.45%in acarbose group.The non-inferiority criterion for primary hypotheses was met for gliclazide and repaglinide,but not for acarbose,compared with glimepiride,when added to metformin/sitagliptin dual therapy.The incidences of adverse events(AEs) were 29.2%in the dual therapy stage and30.3%in the triple therapy stage.Metformin/sitagliptin as baseline therapy,with the addition of a third oral antihyperglycemic agent,including glimepiride,gliclazide,repaglinide,or acarbose,was effective,safe and well-tolerated for achieving an HbAlc<7.0%goal in type 2 diabetic patients inadequately controlled with previous therapies.The timely augmentation of up to three oral antihyperglycemic agents is valid and of important clinical benefit to prevent patients from exposure to unnecessarily prolonged hyperglycemia. | Wen Xu Yiming Mu Jiajun Zhao Dalong Zhu Qiuhe Ji Zhiguang Zhou Bin Yao Anhua Mao Samuel S.Engel Bin Zhao Yan Bi Longyi Zeng Xingwu Ran Juming Lu Linong Ji Wenying Yang Weiping Jia Jianping Weng | 2017 | Science China(Life Sciences)2017，60，3： | 19 |
| 2 | Phosphine oxide-functionalized polyfluorene derivatives:Synthesis,photophysics,electrochemical properties,and electroluminescence performance显示文摘A series of phosphine oxide-functionalized polyfluorene derivatives,PFH-PO-40-1 (P1),PFH-PO-20-1 (P2),PFH-PO-10-1 (P3),and PFH-PO-1-1 (P4),were prepared via a palladium-mediated Suzuki cross-coupling reaction.The structures and purities of all polymers were fully characterized by 1H and 13C NMR,UV-vis and photoluminescent spectroscopy,gel permeation chromatography,and TGA/DSC.Their emission features showed single broad peaks at about 445 nm in film,compared with those in dilute solutions,which might be caused by some degree of aggregation in the excited states of the backbones.The best electroluminescence (EL) performance of these polymers with configuration of ITO/PEDOT:PSS/Polymer/Alq3/LiF/Al was obtained from P1 (current efficiency was 4.2 Cd/A at 6V). | LIU DeAng GIBSON Gary BRUG James LAM Sity MAO Samuel S | 2011 | Science China Chemistry2011，54，4： | 3 |
| 3 | Titanium dioxide nanomaterials: synthesis, properties, modifications, and applieations显示文摘 | CHEN Xiao-bo MAO Samuel S | 2007 | Chemical Reviews2007，107，7： | 1 |
| 4 | Vesicles and Other Self-organized Molecular Assemblies Formation in Nonaqueous Solvents显示文摘 | Huang Michael H Mao Samuel Wu Yiying | 2001 | Science2001，292，8： | 1 |
| 5 | Room-temperature ultraviolet nanowire nanolasers显示文摘 | Huang Michael H Mao Samuel Feick Henning | 2001 | Science2001，292，5523： | 1 |
| 6 | Controlled growth of ZnO nanowires and their optical properties显示文摘 | MICHAEL H HUANG SAMUEL MAO HENNING FEICK | 2001 | Science2001，292，8： | 1 |
| 7 | Titanium dioxide nanomaterials: synthesis, properties, modifications, and applications显示文摘 | Chen Xiaobo Mao Samuel S | 2007 | Chemical Reviews2007，107，： | 1 |
| 8 | Fabrication and characterization of ZnO nanowires based UV photodiodes显示文摘 | LUO Lei ZHANG Yanfeng MAO Samuel S | 2006 | Sensors and Actuators:A2006，127，2： | 1 |
| 9 | 显示文摘 | Michael H Huang Samuel Mao Yang Peidong | 2001 | Science2001，292，5523： | 1 |
| 10 | Room-temperature ultraviolet nanowire nanolasers 显示文摘 | Michael Huang Samuel Mao Henning Feick | 2001 | Science2001，292，： | 1 |
| 11 | Room temperature ultraviolet nanowire nanolasers显示文摘 | Huang Michael H Mao Samuel Feick Henning | 2001 | Science2001，292，5523： | 1 |
| 12 | 显示文摘 | Xiaobo Chen Samuel S Mao | 2007 | Chemical Reviews2007，，： | 1 |
| 13 | Room -Temperature ultraviolet nanowire nanolasers 显示文摘 | Michael H Huang Samuel Mao Henning Feick | 2001 | Science2001，292，： | 1 |
| 14 | ST-segment deviation pattern of takotsubo cardiomyopathy similar to acute pericarditis: Diffuse ST-segment elevation显示文摘 | Zhan Zhong-qun Wang Chong-quan Samuel Sclarovsky Kjell C. Nikus He Chao-rong Mao Shan | 2012 | Journal of Electrocardiology2012，，： | 1 |
| 15 | Room-temperature ultraviolet nanowire nanolasers 显示文摘 | Huang M H Mao Samuel Feick Henning | 2001 | Science2001，292，： | 1 |
| 16 | Controlled Growth of ZnO Nanowires and Their Optical Properties显示文摘 | Yang Peidong Yan Huangquan Mao Samuel | 2002 | Advanced Functional Materials2002，12，5： | 1 |
| 17 | Room-temperature ultraviolet nanowire nanolasers显示文摘 | Huang Michael H Samuel Mao | 2001 | Science2001，292，： | 1 |
| 18 | ST-segment deviation pattern of takotsubo cardiomyopathy similar to acute pericarditis: Diffuse ST-segment elevation显示文摘 | Zhan Zhong-qun Wang Chong-quan Samuel Sclarovsky Kjell C. Nikus He Chao-rong Mao Shan | 2012 | Journal of Electrocardiology2012，，： | 1 |
| 19 | Science显示文摘 | Huang Michael H Mao Samuel Feick Henning | 2001 | 292: 18972001，292，： | 1 |
| 20 | Titanium dioxide nanomaterials:synthesis,properties,modifications and applications显示文摘 | CHEN Xiaobo Samuel S Mao | 2007 | Chem Rev2007，107，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员